These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1701585)

  • 1. Development and evaluation of an enzyme-linked immunoassay for the prostate: specific antigen utilizing two monoclonal antibodies.
    Zundel D; Jarry H; Kestler D; Holzapfel G; Bartels H; Scheit KH; Wuttke W
    Urol Res; 1990; 18(5):327-30. PubMed ID: 1701585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
    Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
    Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
    Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
    Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen in prostatic cancer.
    Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A
    Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
    Saedi MS; Hill TM; Kuus-Reichel K; Kumar A; Payne J; Mikolajczyk SD; Wolfert RL; Rittenhouse HG
    Clin Chem; 1998 Oct; 44(10):2115-9. PubMed ID: 9761243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
    Armitage TG; Cooper EH; Newling DW; Robinson MR; Appleyard I
    Br J Urol; 1988 Dec; 62(6):584-9. PubMed ID: 2464397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ultrasensitive assay development by using monoclonal antibodies for detecting prostate-specific antigen.
    Di Silverio F; D'Eramo G; Flammia GP; Caponera M; Macrí D; Loreto A; Sciarra A
    Eur Urol; 1992; 21 Suppl 1():79-82. PubMed ID: 1385136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.
    Chan DW; Bruzek DJ; Oesterling JE; Rock RC; Walsh PC
    Clin Chem; 1987 Oct; 33(10):1916-20. PubMed ID: 2444361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker.
    Leitenberger A; Altwein JE
    Eur Urol; 1990; 17(1):12-6. PubMed ID: 1690653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
    Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
    Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
    Buamah PK; Johnson P; Skillen AW
    Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen.
    Jurincic-Winkler C; von der Kammer H; Horlbeck R; Klippel KF; Pixberg HU; Scheit KH
    Eur Urol; 1993; 24(4):487-91. PubMed ID: 7507048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
    Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
    Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study.
    Morote Robles J; Ruibal Morell A; Palou Redorta J; de Torres Mateos JA; Soler Roselló A
    Eur Urol; 1988; 14(5):360-6. PubMed ID: 2458936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
    Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
    Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
    Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
    Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
    Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
    Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
    Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
    Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.